Drug Trial Radar · NCT06019728
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Nov 10, 2023
Primary completion
Oct 25, 2024
Study completion Oct 25, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.
Conditions
- Fabry's Disease
Interventions
AGALSIDASE BETA (GZ419828)Drug
Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion
AcetaminophenDrug
Tablet or solution; Oral
DiphenhydramineDrug
Tablet or solution; Oral
DexamethasoneDrug
Tablet or solution; Oral
MontelukastDrug
Tablet or chewable tablet or oral granules; Oral
LoratadineDrug
Tablet or chewable tablet; Oral
CetirizineDrug
Tablet or oral solution; Oral
FexofenadineDrug
Tablet or oral suspension; Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Reduction in Shortest Tolerated Infusion Duration From Pre-study Average of Recent 3 InfusionsTime frame: Up to 16 weeks
- Shortest Actual Tolerated Infusion DurationTime frame: Up to 16 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
UCLA Medical Center Site Number : 1003
Santa Monica, California
Emory University School of Medicine Site Number : 1005
Atlanta, Georgia
Infusion Associates Site Number : 1001
Grand Rapids, Michigan
Metropolitan Hospital Center Site Number : 1004
New York, New York
Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.